Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bottrop – page 113

1 691 clinical trials in Bottrop, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bottrop at a glance
1 691
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 691 trials in Bottrop

Open in trial search

Study on Atezolizumab for Patients with Non-Small Cell Lung Cancer After Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study on Treprostinil Palmitil Inhalation Powder for Patients with Pulmonary Hypertension and Interstitial Lung Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Neoplasm malignant+1

Not recruiting

Study of Niraparib and Dostarlimab for Children with Recurrent or Hard-to-Treat Solid Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of Pembrolizumab, Olaparib, and Pemetrexed for Patients with Stage IV Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Follicular lymphoma

Not recruiting

Study on Mosunetuzumab and Lenalidomide for Patients with Untreated Follicular Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Study of IO102-IO103 and Pembrolizumab for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:IO102 hydrochloride
  • Sponsor:Io Biotech ApS

Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Soft tissue sarcoma

Not recruiting

Study on L19TNF and Doxorubicin for Patients with Advanced or Metastatic Soft Tissue Sarcoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Onfekafusp Alfa
  • Sponsor:Philogen S.p.A.

Study on the Safety and Effectiveness of Apraglutide for Patients with Steroid-Resistant Gastrointestinal Acute Graft Versus Host Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Apraglutide
  • Sponsor:VectivBio AG

Study on the Safety and Effectiveness of Amivantamab and Capmatinib for Patients with Unresectable Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Study to Determine the Best Dose of Vesleteplirsen for Patients with Duchenne Muscular Dystrophy Suitable for Exon 51-Skipping Treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Vesleteplirsen
  • Sponsor:Sarepta Therapeutics Inc.

Study of Relatlimab and Nivolumab with Chemotherapy for Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bottrop

What the registry says about research in the country

01 Breast Cancer Research

Extensive clinical trials focusing on hormone receptor-positive (HR+) and HER2-negative breast cancer treatments, evaluating innovative therapeutic approaches.

  • Early-stage breast cancer treatments
  • Metastatic disease management
  • Targeted therapy combinations

Studies include evaluation of novel drugs like ribociclib, elacestrant, and olaparib in combination with endocrine therapy.

02 Triple Negative Breast Cancer

Research investigating immunotherapy combinations and novel treatment approaches for patients with triple-negative breast cancer.

  • Post-surgery treatment optimization
  • Combination therapy assessment
  • Survival outcome improvements

Clinical trials evaluating sacituzumab govitecan-hziy with pembrolizumab versus standard treatments.

03 Ovarian Cancer Studies

Investigations into treatment strategies for advanced ovarian cancer, including peritoneal and fallopian tube cancers.

  • First-line therapy optimization
  • Combined treatment approaches
  • Progressive disease management

Focus on evaluating niraparib and bevacizumab combinations following chemotherapy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.